Drug Trial Radar · NCT04174898
MSC Infusion for Anti-aging and Regenerative Therapy
Last checked: Nov 20, 2026Latest source record: Nov 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
Apr 15, 2020
Primary completion
Apr 14, 2021
Study completion Apr 14, 2022
Sponsor
- Lead sponsor
- Landmark Medical Centre Sdn BhdAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- CytoMed Therapeutics Pte Ltd
- First posted
- Nov 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of human Mesenchymal Stem Cell (hMSC) infusion therapy, in preserving general wellness and ameliorating or reversing the effects of aging in our study population
Conditions
- Aging Well
- Regenerative Medicine
Interventions
human Mesenchymal Stem Cell (MSC) infusion therapyBiological
Subjects will be infused with 100million human MSCs
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate number of Participants with Treatment-Related Adverse EventsTime frame: 1 year
- Improvement in General Well-Being, as assessed by our 'Quality of Life' Questionnaire, adapted from SF36.Time frame: 1 year
- Change in inflammatory marker levelsTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Landmark Medical Centre Sdn Bhd
Johor Bahru, Johor Darul Takzim, Malaysia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.